All In Biotech

Drug Trial Radar · NCT04706429

The Efficacy and Mechanism of Trientine in Patients With Hypertrophic Cardiomyopathy

A Randomised, Double-blind, Placebo-controlled, Phase 2 Evaluation of the Efficacy and Mechanism of Trientine in Patients With Hypertrophic Cardiomyopathy

Last checked: Nov 20, 2026Latest source record: Sep 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 154 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

154

Actual

Start

Dec 1, 2020

Primary completion

Apr 30, 2024

Study completion Jul 30, 2024

Sponsor

Lead sponsor
Manchester University NHS Foundation TrustGovernment (non-federal)
Sponsor type
Government (non-federal)
Collaborators
National Institute for Health Research, United Kingdom; University of Manchester; University of Liverpool; Univar BV; University of Oxford
First posted
Jan 12, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This research study has been designed to test whether a drug called trientine dihydrochloride (also called Cufence) reduces heart muscle thickening, improves exercise capacity, improves heart function and reduces abnormal heart rhythms in patients with hypertrophic cardiomyopathy (HCM). The study is also assessing how trientine works in HCM. Participants will be prescribed either trientine or placebo, for a period of 12 months.

Conditions

  • Hypertrophic Cardiomyopathy

Interventions

  • TrientineDrug

    Trientine dihydrochloride is a white to pale yellow crystalline hygroscopic powder.

  • PlaceboDrug

    Placebo capsule, manufactured with the exact components of the trientine capsules, without the active ingredient / investigational medicinal product.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Left ventricular mass indexed to body surface area (LVMi)Time frame: 12 months

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • NHS Grampian

    Aberdeen, United Kingdom

  • University Hospitals of Leicester NHS Foundation Trust

    Leicester, United Kingdom

  • Liverpool Heart and Chester Hospital NHS Foundation Trust

    Liverpool, United Kingdom

  • Royal Brompton and Harefield NHS Foundation Trust

    London, United Kingdom

  • Manchester University NHS Foundation Trust

    Manchester, United Kingdom

  • Northumbria Healthcare NHS Foundation Trust

    North Shields, United Kingdom

  • Oxford University Hospitals NHS Foundation Trust

    Oxford, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.